TMCnet15 小时
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA ...
If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population estimated to be approximately 1,000 people. Earlier this month X4 ...
Cure Today14 小时
Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers
Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...